Skip to content

Influence of Lung Recruitment Potential on Positive End-Expiratory Pressure (PEEP) Titration Strategies in Acute Respiratory Distress Syndrome (ARDS) Patients.

Influence of the Lung Recruitment Potential on the Response to Two Positive End-Expiratory Pressure (PEEP) Titration Strategies in Patients With Acute Respiratory Distress Syndrome (ARDS)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07603310
Acronym
RECRUIT-PEEP
Enrollment
52
Registered
2026-05-22
Start date
2026-06-01
Completion date
2027-09-30
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS (Acute Respiratory Distress Syndrome)

Keywords

Acute Respiratory Distress Syndrome, Positive End-Expiratory Pressure, Respiratory Mechanics, Lung Volume Measurements, Esophageal Monitoring, Ventilator-Induced Lung Injury, Artificial Respiration

Brief summary

Acute Respiratory Distress Syndrome (ARDS) is characterized by severe hypoxemia and diffuse alveolar collapse, often requiring invasive mechanical ventilation. Non-individualized mechanical ventilation settings can cause ventilator-induced lung injury (VILI). Positive end-expiratory pressure (PEEP) prevents alveolar collapse, but its effect varies among individuals. The recruitment-to-inflation (R/I) ratio evaluates bedside lung recruitment potential. This pilot study aims to compare two individualized PEEP titration strategies-one guided by the best static respiratory compliance and another guided by transpulmonary pressure via an esophageal balloon-and evaluate how baseline lung recruitment potential alters the early physiological responses to these interventions. Both strategies are preceded by an identical, standardized pressure-controlled initial lung recruitment maneuver to establish a baseline recruitment state.

Detailed description

This is a prospective, randomized, open-label, parallel-group pilot study conducted at the Adult Intensive Care Unit of Hospital Dr. Franco Ravera Zunino (HFRZ). Eligible adult patients under invasive mechanical ventilation with moderate-to-severe ARDS within 36 hours of fulfilling Berlin criteria will be evaluated. Prior to randomization, the patient's recruitment potential will be measured bedside using the R/I ratio (where \> 0.5 indicates high recruitment potential and \<= 0.5 indicates low potential). Eligible participants will then be randomized 1:1 into two PEEP titration groups: 1. PEEP titration targeted to achieve the best static compliance of the respiratory system. 2. PEEP titration guided by transpulmonary pressure measured via an esophageal balloon to target a positive end-expiratory transpulmonary pressure. Crucially, immediately before starting the specific PEEP titration protocol in either group, an identical, standardized lung recruitment maneuver will be performed. This maneuver is executed in pressure-controlled ventilation (PCV) with a control pressure of 15 cmH2O, I:E ratio of 1:1, FiO2 1.0, starting with PEEP 5 cmH2O and increasing by 5 cmH2O every 10 seconds up to PEEP 25 cmH2O, maintaining a maximum peak pressure limit of 40 cmH2O for exactly 1 minute. Standard baseline ventilator parameters will follow protective ventilation targets: volume-controlled ventilation, tidal volume 6-8 mL/kg of predicted body weight, respiratory rate adjusted to keep pH 7.25-7.45, plateau pressure \< 28 cmH2O, and driving pressure \< 14 cmH2O. Physiological parameters (PaO2/FiO2, driving pressure, ventilatory ratio, static compliance) will be recorded at 1, 24, 48, and 72 hours. The primary outcome is the change in oxygenation (PaO2/FiO2 ratio) at 24 hours. The study will explore how the baseline phenotype of lung recruitability alters early mechanical and gas exchange outcomes.

Interventions

PROCEDUREPositive End-Expiratory Pressure (PEEP) Titration guided by Static Compliance

Positive End-Expiratory Pressure (PEEP) Titration by Static Compliance: Following the initial recruitment maneuver, an individualized PEEP decremental titration step-protocol is performed to identify the specific PEEP level that maximizes the static compliance of the respiratory system, aiming to optimize the balance between alveolar recruitment and overdistension. Initial Lung Recruitment Maneuver : Prior to individualized PEEP titration, all participants in this arm will undergo an initial standardized lung recruitment maneuver. This procedure will be executed in Pressure-Controlled Ventilation (PCV) mode, utilizing a driving/control pressure of 15 cmH2O. The recruitment process will begin at a baseline Positive End-Expiratory Pressure (PEEP) of 5 cmH2O, followed by incremental steps of 5 cmH2O every 10 seconds until reaching a maximum PEEP of 25 cmH2O. A peak airway pressure limit of 40 cmH2O will be strictly maintained during the maneuver for a total duration of 1 minute.

PROCEDUREPositive End-Expiratory Pressure (PEEP) Titration guided by Transpulmonary Pressure

Positive End-Expiratory Pressure (PEEP) Titration by Transpulmonary Pressure: Following the initial recruitment maneuver, PEEP is titrated and protocolized via real-time esophageal balloon monitoring to target and maintain a slightly positive expiratory transpulmonary pressure, minimizing cyclic alveolar collapse and overdistension. Initial Lung Recruitment Maneuver: Prior to individualized PEEP titration, all participants in this arm will undergo an initial standardized lung recruitment maneuver. This procedure will be executed in Pressure-Controlled Ventilation (PCV) mode, utilizing a driving/control pressure of 15 cmH2O. The recruitment process will begin at a baseline Positive End-Expiratory Pressure (PEEP) of 5 cmH2O, followed by incremental steps of 5 cmH2O every 10 seconds until reaching a maximum PEEP of 25 cmH2O. A peak airway pressure limit of 40 cmH2O will be strictly maintained during the maneuver for a total duration of 1 minute.

Sponsors

Hospital Dr. Franco Ravera Zunino
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective, randomized, parallel-group, open-label, exploratory clinical trial. Patients are stratified or analyzed according to their baseline lung recruitment potential (high vs. low, determined by the Recruitment/Inflation \[R/I\] ratio) and randomized to receive one of two early individualized Positive End-Expiratory Pressure (PEEP) titration strategies. Both arms undergo an identical initial lung recruitment maneuver prior to titration

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of moderate or severe Acute Respiratory Distress Syndrome (ARDS) according to the Berlin definition: acute onset, bilateral opacities not fully explained by heart failure or fluid overload, and Partial pressure of oxygen in arterial blood/Fraction of inspired oxygen \<= 200 mmHg with Positive End-Expiratory Pressure (PEEP) \>= 5 cmH2O. * ARDS duration \< 36 hours since fully meeting Berlin consensus criteria. * Relative hemodynamic stability: absence of refractory shock, defined as norepinephrine dose \<= 0.5 mcg/kg/min.

Exclusion criteria

* Evidence of active pulmonary air leaks (bronchopleural fistula, pneumothorax, pneumomediastinum). * Severe uncorrected hemodynamic instability (norepinephrine \> 0.5 mcg/kg/min). * Contraindications for esophageal balloon placement (esophageal obstruction, known perforation, recent esophageal surgery, severe esophagitis). * Elevated intracranial pressure or conditions where hypercapnia-induced increases in intracranial pressure must be avoided (intracranial hemorrhage, cerebral contusion, cerebral edema, mass effect with midline shift on CT). * Known pregnancy. * Severe coagulopathy (platelet count \< 5,000/uL or INR \> 3). * Airway opening pressure higher than 15 cmH2O (AOP \> 15 cmH2O). * History of severe neuromuscular disease or chronic respiratory disease. * Having received invasive mechanical ventilation for more than 96 hours. * Inability to obtain informed consent or refusal by the legal representative. * Contained laparotomy (open abdomen).

Design outcomes

Primary

MeasureTime frameDescription
Change in Early Oxygenation (PaO2/FiO2 Ratio).Baseline and 24 hours post-PEEP titrationThe change in gas exchange efficiency is calculated as the absolute difference between the baseline Partial pressure of oxygen in arterial blood (PaO2)/Fraction of inspired oxygen (FiO2) ratio and the PaO2/FiO2 ratio measured 24 hours after individualized Positive End-Expiratory Pressure (PEEP) titration.

Secondary

MeasureTime frameDescription
Evolution of Static Compliance of the Respiratory SystemBaseline, 1, 24, 48, and 72 hoursChanges in static compliance calculated via the formula: Tidal Volume / (Plateau Pressure - Positive End-Expiratory Pressure).
Evolution of Driving Pressure and Plateau PressureBaseline, 1, 24, 48, and 72 hoursSerial monitoring of driving pressure (Plateau Pressure - Positive End-Expiratory Pressure) and plateau pressure to evaluate lung stress.
Ventilatory EfficiencyBaseline, 24, 48, and 72 hoursEvaluated using the Ventilatory Ratio (VR), which correlates physiological dead space and minute ventilation.
Incidence of Elevated Airway Opening Pressure (AOP)Pre-randomization (Baseline)Proportion of patients exhibiting an airway opening pressure greater than 5 cmH2O.
Ventilator-Free Days (VFD)Up to Day 28Number of days alive and free from invasive mechanical ventilation within a 28-day window.
Incidence of Procedure-Related Adverse EventsThroughout mechanical ventilation (Up to 28 days)Proportion of participants experiencing complications due to recruitment maneuvers or Positive End-Expiratory Pressure (PEEP) titration (e.g., severe hypotension, barotrauma).

Countries

Chile

Contacts

CONTACTEsteban Santis, RT.
esteban.santis@ogb.cl940367716
CONTACTHospital Dr. Franco Ravera Zunino
carolina.lindsay.brain@gmail.com729383
STUDY_CHAIRFrancisco Cerda, RT.

Hospital Dr. Franco Ravera Zunino

STUDY_CHAIRJavier Astudillo, MD.

Hospital Dr. Franco Ravera Zunino

STUDY_CHAIRJennifer Ayuso, RT.

Hospital Dr. Franco Ravera Zunino

STUDY_CHAIRRodrigo Arevalo, RT.

Hospital Dr. Franco Ravera Zunino

STUDY_CHAIRCarlos Pellegrini, MD.

Hospital Dr. Franco Ravera Zunino

PRINCIPAL_INVESTIGATOREsteban Santis, RT.

Hospital Dr. Franco Ravera Zunino

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026